Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clinical Ophthalmology 2013, Volume 7: 1867-1875. PMID: 24092965, PMCID: PMC3788817, DOI: 10.2147/opth.s32177.Peer-Reviewed Original ResearchCentral serous chorioretinopathySerous chorioretinopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsSafety of PDTTreatment of CSCRPhotodynamic therapyChronic recurrent formGrowth factor agentsPermanent visual lossPossible pathophysiologic mechanismsSerous retinal detachmentProspective interventional studyLong-term efficacyPigment epithelial detachmentPotential therapeutic optionEfficacy of PDTMajority of casesFactor agentsAnatomic improvementFoveal atrophyPigment epitheliopathyRetinal detachmentVisual lossFluorescein angiography